CD22 as a Target for Hematological Malignancies and Autoimmune Diseases
Xin Chen, Jiayi Zhang, Sizhuo Chen, Chaojun Yan, Cefan Zhou, Jingfeng Tang, Rachael Mira McLean, Zhenhuan Zhao · 2026
Read CD22 as a Target for Hematological Malignancies and Autoimmune Diseases by Xin Chen, Jiayi Zhang, Sizhuo Chen, Chaojun Yan, Cefan Zhou, Jingfeng Tang, Rachael Mira McLean, Zhenhuan Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13299070.txt.
Description
A B-cell surface protein called CD22 has become a versatile target across blood cancers and autoimmune disease, review Xin Chen and co-authors in 2026. CD22 sits almost exclusively on B cells, dampens their receptor signaling, and is quickly swallowed into the cell, a combination drug developers prize.
The review tours the arsenal built against it: immunotoxins, radioactive antibodies, antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies. Single-target treatments already achieve high response rates, and pairing CD22 with CD19 in dual-target CAR T cells reduces the antigen escape that causes relapse. The authors trace the same strategies migrating from oncology into autoimmune care and sketch research priorities.
Catalog record
| CREATOR | Xin Chen, Jiayi Zhang, Sizhuo Chen, Chaojun Yan, Cefan Zhou, Jingfeng Tang, Rachael Mira McLean, Zhenhuan Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41618 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |